Hudson Bay Capital Management LP Crispr Therapeutics Ag Transaction History

Hudson Bay Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $907,800 - $1.18 Million	-20,000 Reduced 66.67%	10,000 $453,000
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $1.3 Million - $2.03 Million	-30,000 Reduced 50.0%	30,000 $1.68 Million
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $885,600 - $1.21 Million	-21,600 Reduced 26.47%	60,000 $2.71 Million
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $2.61 Million - $4.37 Million	66,600 Added 444.0%	81,600 $3.32 Million
Q2 2022 Aug 12, 2022	SELL	$43.23 - $73.83 $864,599 - $1.48 Million	-20,000 Reduced 57.14%	15,000 $912,000
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $601,047 - $895,412	11,300 Added 47.68%	35,000 $2.2 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $434,558 - $689,998	6,200 Added 35.43%	23,700 $1.8 Million
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $1.1 Million - $1.57 Million	10,000 Added 133.33%	17,500 $1.96 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $756,300 - $1.21 Million	-7,500 Reduced 50.0%	7,500 $1.21 Million
Q1 2021 May 14, 2021	BUY	$110.72 - $210.04 $1.66 Million - $3.15 Million	15,000 New	15,000 $1.83 Million

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.